EGFR and prostate cancer: In this study, we found that CFF‐1 targeted EGFR and competitively acted on EGFR with EGF and then inhibited auto‐phosphorylation and activity of EGFR thus inhibiting PI3K/AKT and Raf/Erk signal pathways by decreasing the phosphorylation levels of PI3K, AKT, Raf, and Erk in both androgen‐dependent and androgen‐independent prostate cancer cells (LNCaP and PC3 cells).